Sign up for ICER's Weekly View Newsletter

 

Weekly View


May 29, 2026

From the desk of Priya Ranade

Good morning, everyone.

ICER will assess two treatments for Friedrich’s Ataxia, a rare neurological illness. The treatments in scope include:

 

  • nomlabofusp (Larimar Therapeutics, Inc.)


  • omaveloxolone (Skyclarys®, Biogen Inc.) 

 

Consistent with ICER’s process for announcing new assessments, we have spent the past five weeks conducting outreach and engaging with targeted stakeholders, including relevant patient groups, the manufacturers, and clinical experts. Based on this preliminary cross-stakeholder engagement, ICER posted a Draft Scoping Document outlining how we plan to conduct this assessment, which will be open to public comment until June 16th.

Let's see what else happened this week...

 

ICER in the News

 

ICER Scientific Advice Webinar: Setting Your Company Up For Success

Were you unable to attend this week’s webinar on ICER Scientific Advice (ISA)? Rachel Salzman, CEO of Armatus Bio, shared her experiences with the ISA program. Listen now!

 

ISA is a new offering from ICER that advises companies with clinical stage assets on evidence generation strategies to support a more comprehensive assessment of clinical effectiveness and value. Contact us to learn more.

ICER report demonstrates both the value and challenges in financing of weight loss medications

Journal of Managed Care and Specialty Pharmacy (JMCP) 

JMCP recently published a report on the importance of access to GLP-1 obesity medications. The authors stated:

 

“The primary takeaway from this [ICER] report is the fact that these medications represent a remarkable advancement of modern medicine and present tremendous value for addressing the chronic disease epidemic in the United States.”

 

In the past year, ICER published two reports in the obesity space: 1) a White Paper on strategies to ensure affordable access for obesity medications and 2) a review on Wegovy (semaglutide) and Zepbound (tirzepatide) for obesity management, which found both therapies are highly cost-effective.

 
Pharmaceutical News

MUST READS

To Rebuild Trust, FDA Should Start With The Accelerated Approval Program

Health Affairs

Health Affairs published an op-ed by Anna Kaltenboeck, President of Verdant Research, where she reflected on potential reforms to the accelerated approval pathway:


"For serious conditions with high unmet need, earlier access to promising treatments can be worth the risk of greater uncertainty. But achieving this balance demands more than good intentions or even promising policy ideas. It demands trust shared by all parties involved including patients, payers, and manufacturers. It also requires that the trust of the public—whose health depends on a functioning regulatory apparatus—be earned through consistent, transparent, science-driven decision-making."


ICER recently collaborated with Verdant Research to publish a new white paper titled, “Strengthening the FDA's Accelerated Approval Pathway: Progress and Unfinished Business,” which reviews recent regulatory and market changes and identifies several policies that could be adopted to further improve the pathway. 


2026 Milliman Medical Index

Milliman

The 2026 Milliman Medical Index was published this month. They found that the cost of care for a family of four increased significantly in the past year: 

 

“In 2026, the cost of healthcare for a hypothetical American family of four covered by an average employer-sponsored health plan is $37,824, according to the Milliman Medical Index (MMI)… Compared to the 2025 MMI, healthcare costs for the average person increased 7.9%, from $7,838 to $8,460. This is the highest increase for the MMI in more than a decade, excluding the fluctuations experienced as a result of the COVID-19 pandemic. Outpatient facility care and pharmacy services continue to be the primary categories driving cost increases, with outpatient facility costs rising 7.5% and pharmacy costs rising 14.8% over last year. These two categories alone contributed 69% of the year-over-year increase in the MMI for the average person.”

Cost Plus Drugs Beats Commercial Insurance Co-Pays 80% of the Time

American Journal of Managed Care (AJMC)

Generic prescriptions with cost-sharing above $15 under employer-sponsored insurance could be purchased for less at the Mark Cuban Cost Plus Drug Company (MCCPDC) nearly 80% of the time, according to a brief report published in Annals of Internal Medicine. For drugs with cost-sharing above $100, patients could save a median of $119 per prescription using MCCPDC.


The findings provide a data-driven framework for when commercially insured patients may actually be better off bypassing their insurance altogether and paying cash through a direct-to-consumer (DTC) pharmacy.

RFK Jr., states at odds over cause of Obamacare’s enrollment declines

Politico

Both the Trump administration and state officials agree on the numerical fact: People this year are dropping their Obamacare coverage — to the tune of 1.2 million people out of a total enrollment of 24.3 million as of March, according to the latest federal data. But they are at odds over why.

 

Trump officials say better federal policing of fraud on Healthcare.gov accounts for much of the drop. Meanwhile, some state Affordable Care Act exchanges blame higher costs, particularly after Congress decided not to extend beyond Jan. 1 the enhanced subsidies that brought premiums down for higher-income people.

U.S. Health Care from a Global Perspective, 2026

The Commonwealth Fund

The Commonwealth Fund recently released a report examining the health care systems of 20 countries, including the US. The report includes analyses on: 1) insurance coverage and access to care, 2) affordability of care, 3) delivery of care, and 4) equity of health outcomes. The authors stated:

 

“The U.S., on average, has the poorest health outcomes of any high-income country, and among the poorest of the high- and middle-income nations belonging to the Organisation for Economic Co-operation and Development (OECD). Lack of universal coverage, weak primary care infrastructure, high out-of-pocket costs, and a complex insurance system contribute to and exacerbate the nation’s uniquely poor performance relative to its peers.”

OTHER HEADLINES

 

Join ICER!

 

Want to work for a fast-paced, mission-driven organization? Look no further! ICER is looking to expand our team:



 

Key Upcoming Dates

 
  • 6/8: Narcolepsy -- Final Evidence Report
  • 6/11: Covid-19 -- Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email